These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29118871)

  • 1. Gastroesophageal Reflux Disease Associated With Anxiety: Efficacy and Safety of Fixed Dose Combination of Amitriptyline and Pantoprazole.
    Faruqui AA
    Gastroenterology Res; 2017 Oct; 10(5):301-304. PubMed ID: 29118871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of pantoprazole and itopride in patients with overlap of gastroesophageal reflux disease and dyspepsia: A prospective, open-label, single-arm pilot study.
    Lakhtakia S; Singh AP; Singla N; Memon SF; Reddy DN
    JGH Open; 2024 Feb; 8(2):e12988. PubMed ID: 38344252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease - PAN-STAR.
    Dabrowski A; Štabuc B; Lazebnik L
    Prz Gastroenterol; 2018; 13(1):6-15. PubMed ID: 29657605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relief of Night-time Symptoms Associated With Gastroesophageal Reflux Disease Following 4 Weeks of Treatment With Pantoprazole Magnesium: The Mexican Gastroesophageal Reflux Disease Working Group.
    López-Alvarenga JC; Orr W; Vargas-Romero JA; Remes-Troche JM; Morales-Arámbula M; Soto-Pérez JC; Mateos-Pérez G; Sobrino-Cossío S; Teramoto-Matsubara O; López-Colombo A; Orozco-Gamiz A; Saez-Ríos A; Arellano-Plancarte A; Chiu-Ugalde J; Tholen A; Horbach S; Lundberg L; Fass R
    J Neurogastroenterol Motil; 2014 Jan; 20(1):64-73. PubMed ID: 24466446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study.
    Remes-Troche JM; Sobrino-Cossío S; Soto-Pérez JC; Teramoto-Matsubara O; Morales-Arámbula M; Orozco-Gamiz A; Tamayo de la Cuesta JL; Mateos G
    Clin Drug Investig; 2014 Feb; 34(2):83-93. PubMed ID: 24347282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
    van Zyl J; van Rensburg C; Vieweg W; Fischer R
    Digestion; 2004; 70(1):61-9. PubMed ID: 15297779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [What is the utility of proton pump inhibitor testing in non-cardiac chest pain?].
    Huamán JW; Aliaga V; Domenech G; Videla S; Saperas E
    Gastroenterol Hepatol; 2014 Oct; 37(8):452-61. PubMed ID: 24725608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease.
    Pai VG; Pai NV; Thacker HP; Shinde JK; Mandora VP; Erram SS
    World J Gastroenterol; 2006 Oct; 12(37):6017-20. PubMed ID: 17009401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Additive Effect of Domperidone on Patients with Refractory Gastroesophageal Reflux Disease; A Randomized Double Blind Clinical Trial.
    Taghvaei T; Kazemi A; Hosseini V; Hamidian M; Tirgar Fakheri H; Hashemi SA; Maleki I
    Middle East J Dig Dis; 2019 Jan; 11(1):24-31. PubMed ID: 31049179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
    Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
    Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD.
    Winter H; Kum-Nji P; Mahomedy SH; Kierkus J; Hinz M; Li H; Maguire MK; Comer GM
    J Pediatr Gastroenterol Nutr; 2010 Jun; 50(6):609-18. PubMed ID: 20400912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine.
    Paré P; Armstrong D; Pericak D; Pyzyk M
    J Clin Gastroenterol; 2003 Aug; 37(2):132-8. PubMed ID: 12869883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: a randomized, double-blind comparative trial.
    Cho YK; Choi MG; Bak YT; Rhee PL; Kim SG; Jung HY; Seol SY
    Dig Dis Sci; 2012 Dec; 57(12):3189-94. PubMed ID: 22772870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Dose Pantoprazole for Gastroesophageal Reflux Disease: Need, Evidence, Guidelines and Our Experience.
    Upadhyay R; Soni NK; Kotamkar AA; Naseem A; Phadke A; Nayar S; Pallewar S; Shetty P; Mungantiwar A; Jaiswal S; Qamra A
    Euroasian J Hepatogastroenterol; 2024; 14(1):86-91. PubMed ID: 39022196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study.
    Körner T; Schütze K; van Leendert RJ; Fumagalli I; Costa Neves B; Bohuschke M; Gatz G
    Digestion; 2003; 67(1-2):6-13. PubMed ID: 12743434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.
    Haag S; Holtmann G
    Clin Ther; 2010 Apr; 32(4):678-90. PubMed ID: 20435237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease.
    Tolia V; Bishop PR; Tsou VM; Gremse D; Soffer EF; Comer GM;
    J Pediatr Gastroenterol Nutr; 2006 Apr; 42(4):384-91. PubMed ID: 16641576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open access capture of patients with gastroesophageal reflux disease using an online patient-reported outcomes instrument.
    Tielemans MM; Jansen JB; van Oijen MG
    Interact J Med Res; 2012 Sep; 1(2):e7. PubMed ID: 23611985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms.
    Scholten T; Gatz G; Hole U
    Aliment Pharmacol Ther; 2003 Sep; 18(6):587-94. PubMed ID: 12969085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychological distress is not associated with treatment failure in patients with gastroesophageal reflux disease.
    Boltin D; Boaz M; Aizic S; Sperber A; Fass R; Niv Y; Dickman R
    J Psychosom Res; 2013 Nov; 75(5):462-6. PubMed ID: 24182636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.